拟议生物类似药阿柏西普SDZ-AFL治疗新生血管性年龄相关性黄斑变性的疗效与安全性:3期Mylight研究52周结果
3期Mylight研究为前瞻性、双盲、双臂、平行设计,将新生血管性年龄相关性黄斑变性患者按1:1随机分配接受48周内8次SDZ-AFL(n=244)或Ref-AFL(n=240)注射。第8周最佳矫正视力评分平均变化差异为-0.3(90%CI,-1.5至1.0),第52周也显示相似性;两组解剖学结局无临床意义差异,治疗相关不良事件发生率相近(SDZ-AFL:2.5%;Ref-AFL:2.9%),抗药抗体发生率相似,给药后24小时全身游离阿柏西普浓度低且可比。
要点
- 第8周BCVA评分平均变化SDZ-AFL与Ref-AFL差异为-0.3(90%CI,-1.5至1.0)。
- 治疗相关不良事件发生率SDZ-AFL为2.5%,Ref-AFL为2.9%。
- 两组抗药抗体发生率及给药后24小时全身游离阿柏西普浓度相似。
核心结论
- 拟议生物类似药阿柏西普SDZ-AFL在新生血管性年龄相关性黄斑变性患者中,疗效、安全性和药代动力学与参照阿柏西普Ref-AFL相匹配。
- 该3期研究证实SDZ-AFL与Ref-AFL具有生物相似性。
研究设计与样本
- Mylight为前瞻性、双盲、双臂、平行3期研究。
- 新生血管性年龄相关性黄斑变性患者按1:1随机接受48周内8次SDZ-AFL(n=244)或Ref-AFL(n=240)注射。
- 主要终点为基线至第8周最佳矫正视力评分平均变化。
- 次要终点包括解剖学结局、第24周和第52周最佳矫正视力、安全性和药代动力学。
主要发现
- 第8周最佳矫正视力评分平均变化SDZ-AFL(n=235)与Ref-AFL(n=226)差异为-0.3(90%CI,-1.5至1.0),第52周也显示相似性。
- 两组解剖学结局无临床意义差异。
- 治疗相关不良事件发生率SDZ-AFL为2.5%,Ref-AFL为2.9%。
- 两组抗药抗体发生率相似。
- 给药后24小时全身游离阿柏西普浓度低且SDZ-AFL与Ref-AFL可比。
关键数值与推荐
- 第8周BCVA评分平均变化差异SDZ-AFL vs Ref-AFL为-0.3(90%CI,-1.5至1.0)。
- 治疗相关不良事件发生率SDZ-AFL 2.5% vs Ref-AFL 2.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Phase 3 Mylight study was designed to confirm clinical equivalence of proposed biosimilar aflibercept (SOK583A1; Sandoz [proposed biosimilar aflibercept, SDZ-AFL]) to its reference biologic (Eylea; Regeneron Pharmaceuticals, Inc; Bayer AG [reference aflibercept, Ref-AFL]). METHOD: Mylight was a prospective, double-masked, 2-arm, parallel Phase 3 study. Participants with neovascular age-related macular degeneration were randomized 1:1 to receive eight injections of SDZ-AFL (n = 244) or Ref-AFL (n = 240) over 48 weeks. The primary endpoint was mean change in best-corrected visual acuity score from baseline to Week 8. Secondary endpoints included anatomical outcomes, best-corrected visual acuity at Weeks 24 and 52, safety, and pharmacokinetics. RESULTS: Similarity in mean change in best-corrected visual acuity score was established between SDZ-AFL (n = 235) and Ref-AFL (n = 226) at Week 8 (difference: -0.3 [90% CI, -1.5 to 1.0]) and Week 52. No clinically meaningful differences occurred between groups in anatomical outcomes. Safety profiles were similar, with comparable incidences of treatment-related adverse events (SDZ-AFL: 2.5%; Ref-AFL: 2.9%). The incidence of anti-drug antibodies was similar between groups. Systemic free aflibercept concentrations 24 hours postdose were low and comparable between SDZ-AFL and Ref-AFL. CONCLUSION: Proposed biosimilar aflibercept matched reference aflibercept in efficacy, safety, and pharmacokinetics in participants with neovascular age-related macular degeneration. Therefore, this Phase 3 study confirmed biosimilarity of SDZ-AFL to Ref-AFL.
引用
- Bordon AF, Kaiser PK, Wolf A, et al. EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results From the Phase 3 Mylight Study. Retina. 2024. PMID: 39287533. doi:10.1097/IAE.0000000000004174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。